Analysts Adjust Price Targets for ORIC Pharmaceuticals Following FourthQuarter Financial Results
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) recently disclosed their fourth-quarter financial results, showing a loss of 49 cents per share, which ...
Tag: ORIC
Wedbush Analyst Reaffirms Bullish Rating on ORIC Pharmaceuticals with Increased Price Target
Wedbush analyst David Nierengarten has reaffirmed his bullish rating on ORIC Pharmaceuticals (NASDAQ: ORIC) and increased the price target to ...
Analyst Initiates Coverage on ORIC Pharmaceuticals with Overweight Rating
On February 23, 2024, analyst Prakhar Agrawal from Cantor Fitzgerald began covering ORIC Pharmaceuticals (NASDAQ: ORIC) with an Overweight rating. ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Regulatory Shift Sparks Potential Breakthrough for DeFi Technologies
